SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001072613-20-000019
Filing Date
2020-02-04
Accepted
2020-02-04 17:19:46
Documents
1
Group Members
ALI BEHBAHANIANTHONY A. FLORENCE, JR.CARMEN CHANGDAVID M. MOTTFOREST BASKETTJOSHUA MAKOWERMOHAMAD H. MAKHZOUMINEA 16 GP, LLCNEA PARTNERS 16, L.P.NEW ENTERPRISE ASSOCIATES 16, L.P.PAUL WALKERPETER W. SONSINISCOTT D. SANDELL

Document Format Files

Seq Description Document Type Size
1 GROWTH EQUITY OPPORTUNITIES FUND V, LLC - TRILLIUM THERAPEUTICS INC. -- SCHEDULE trill_geo5_18360.htm SC 13D/A 578685
  Complete submission text file 0001072613-20-000019.txt   580628
Mailing Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9
Business Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9 (416) 595-0627
Trillium Therapeutics Inc. (Subject) CIK: 0001616212 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1214
Type: SC 13D/A | Act: 34 | File No.: 005-88719 | Film No.: 20574933
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093
Business Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 410-842-4000
Growth Equity Opportunities V, LLC (Filed by) CIK: 0001706444 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A